SAMUEL LYNCH, DMSc, DMD, is a highly successful serial biotech CEO and founder focused in the regenerative medicine field. He holds two doctorates, one from Harvard Medical School (DMSc), where he has received the Distinguished Alumnus award. He has over 250 publications and patents, and given hundreds of lectures in ~ 25 countries. He has founded and grown three hybrid biotech/medtech companies, today with an estimated value well in excess of $1 billion, including BioMimetic Therapeutics which he took public on Nasdaq and sold for approximately $400 million. His patented combination products have been used to improve healing and tissue regeneration in over 5 million patients. He is also a Founding Member of the governing Board of Directors of the Vanderbilt University Medical Center (VUMC), where he chaired both the Audit & Compliance and Compensation & Leadership Development committees over his eight year tenure. He has been recognized as one of the individuals with the greatest impact on advancement of medical devices in the United States.
